Rigel Pharma (RIGL) Reports In-Line Q1 Loss
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $46.64 +1.72%
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $5 million versus the consensus estimate of $4 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Amneal gets FDA approval for lanreotide injection, launches immediately
- Arrive AI and DXC Technology partner to bring delivery tech to factories
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
